CClinicalTrials.gg
CompletedNCT02606708Updated Aug 14, 2020Results posted

Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy

An interventional study of Accelerated intensity modulated radiation therapy (AIMRT) in Breast Cancer, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to female participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-08-14.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 7 months after the study started (first participant enrolled Feb 2005, registered Sep 2015).
Phase
Not applicable
Study type
Interventional
Enrollment
314
Allocation
Not applicable
Ages
19 Years to 90 Years
Sex
Female
01

Study summary

The primary purpose of this study is to determine the feasibility and tolerability of a regimen of accelerated (hypofractionated) Intensity Modulated Radiation Therapy (AIMRT) to the whole breast as part of breast preservation. In addition, the investigators want to prospectively collect blood specimens to: assess TGF-β polymorphisms to identify potential carriers at higher risk for post-treatment fibrosis; generate a blood specimen repository for future studies of other relevant polymorphisms. The study investigators also want to prospectively follow each treated woman yearly to assess long-term radiation sequelae of the current regimen by using the LENT/SOMA scores.

Read the detailed description

Despite level I evidence of comparable efficacy to that of mastectomy, breast conserving therapy (BCT) remains underutilized in the United States. In 1990, the National Institutes of Health (NIH) Consensus Development Conference concluded that BCT was the appropriate method of treatment for the majority of women with early stage I and II breast cancer. However, this subsequently only translated in a moderate increase in the utilization of BCT, shifting from 34% to 60% for stage I breast cancer and from 19% to 39% for stage II breast cancer.

There appear to be multiple causes for underutilization. The demands of the standard radiation schedule probably play the main role. Generally, post-lumpectomy radiation therapy consists of 4 to 5 weeks of whole breast radiation of a total dose 45 to 50 Gy in 23-25 fractions, usually followed by a boost of 10 to 16 Gy in 5-8 fractions to the tumor bed area. The total length of treatment is 5-7 weeks, commonly six weeks. Practically, women who choose BCT automatically commit to a regimen of approximately six weeks of daily radiation visits (Monday to Friday) to complete the local management of their breast cancer. For many women, concerns about this commitment are likely to influence the choice for mastectomy instead of breast preservation since only 40-60% of women who meet criteria for BCT actually undergo the procedure. In addition to possible biases of the primary health care provider affecting these choices, it is known that distance from RT treatment facilities also plays an important role in women's choice for mastectomy instead of BCT. Unfortunately, 15-30% of patients who have actually selected BCT, in particularly older patients and those with 2 or more co-morbid conditions, do not receive postoperative RT. These facts warrant a critical assessment of standard radiation therapy in this clinical setting.

The actual standard approach to post-segmental mastectomy adjuvant radiation at our institution consists of surgical excision followed by 6 weeks of breast irradiation for a total of 30 fractions of 2 Gy each, 23 (46 Gy) to the whole breast while 7 to the original tumor bed (14 Gy). Instead, the women in this study will only receive 15 larger radiation fractions (2.7 Gy) to the entire breast with a concomitant boost to the tumor bed (2.7 Gy + .5 Gy, total 3.2 Gy per fraction). All women will be treated prone to best apply IMRT techniques while avoiding the rest of the body.

Treatment with fewer fractions over a shorter duration of time offers several advantages, provided it is as effective as the conventional treatment regimens and without added morbidity. The potential advantages include: 1) less time away from homes, families and jobs; 2) less cost associated with travel and time away from work; 3) ease the demand on radiation treatment resources and produce savings to the health-care system. Moreover, treatment prone assures that only minimal dose of radiation is delivered to the lung, heart and to the controlateral breast.

Patients will have completed all breast surgical procedures prior to accrual into this protocol in order to establish eligibility criteria. All patients will then be treated prone with 2.7 Gy/fraction delivered in 15 fractions over a 3-week period for a total dose of 40.5 Gy.

All patients will be followed 1, 3, 6, 12 months after treatment course, then yearly thereafter.

02

Conditions studied

  • Breast Cancer
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pre- or post-menopausal women with Stage I and II breast cancer
  • Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
  • Status post segmental mastectomy. and after sentinel node biopsy and/or axillary node dissection
  • At least 2 weeks from last chemotherapy
  • Tumors \< 5 mm do not require nodal assessment

Exclusion criteria

Exclusion Criteria:

  • Previous radiation therapy to the ipsilateral breast.
  • More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary radiation.
  • Active connective tissue disorders, such as lupus or scleroderma.
  • Prior or concurrent malignancy other than basal or squamous cell skin cancer or carcinoma in-situ of the cervix, unless disease-free > 5 years.
  • Pregnant or lactating women.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Accelerated intensity modulated radiation therapy (AIMRT)

    All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.

    Radiation: Accelerated intensity modulated radiation therapy (AIMRT)

Interventions

  • RadiationAccelerated intensity modulated radiation therapy (AIMRT)
06

What researchers measure

Primary outcomes

  1. Number of Participants With Local Recurrence in Breast

    Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.

    Time frame: 5 years

  2. Number of Participants With Regional Recurrence

    Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.

    Time frame: 5 years

  3. Number of Participants With Contralateral Breast Cancer

    Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.

    Time frame: 5 years

  4. Number of Participants With Distant Metastases

    number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means

    Time frame: 5 years

  5. Number of Participants With an Outcome of Death

    Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis

    Time frame: 5 years

Secondary outcomes

  1. Maximum Grade Late Radiation Toxicity

    Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.

    Time frame: 5 years

  2. Patient Self-assessment of the Cosmetic Results

    Time frame: 5 years

  3. Survival

    Time frame: 5 years

07

Results

Posted Aug 14, 2020

Participant flow

Participant flow — Overall Study
MilestoneAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Started314
Completed314
Not completed0

Outcome measures

PrimaryNumber of Participants With Local Recurrence in Breast

Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.

Time frame:
5 years
Reported as:
Count of participants · Participants
Number of Participants With Local Recurrence in Breast
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Number of Participants With Local Recurrence in Breast6
PrimaryNumber of Participants With Regional Recurrence

Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.

Time frame:
5 years
Reported as:
Count of participants · Participants
Number of Participants With Regional Recurrence
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Number of Participants With Regional Recurrence4
PrimaryNumber of Participants With Contralateral Breast Cancer

Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.

Time frame:
5 years
Reported as:
Count of participants · Participants
Number of Participants With Contralateral Breast Cancer
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Number of Participants With Contralateral Breast Cancer2
PrimaryNumber of Participants With Distant Metastases

number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means

Time frame:
5 years
Reported as:
Count of participants · Participants
Number of Participants With Distant Metastases
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Number of Participants With Distant Metastases8
PrimaryNumber of Participants With an Outcome of Death

Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis

Time frame:
5 years
Reported as:
Count of participants · Participants
Number of Participants With an Outcome of Death
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Number of Participants With an Outcome of Death17
SecondaryMaximum Grade Late Radiation Toxicity

Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.

Time frame:
5 years
Reported as:
Count of participants · Participants
Maximum Grade Late Radiation Toxicity
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Pigmentation Change — Grade 162
Pigmentation Change — Grade 22
Pigmentation Change — Grade 30
Breast Fibrosis — Grade 159
Breast Fibrosis — Grade 213
Breast Fibrosis — Grade 31
Breast Retraction — Grade 146
Breast Retraction — Grade 217
Breast Retraction — Grade 32
Breast Telangiectasia — Grade 147
Breast Telangiectasia — Grade 219
Breast Telangiectasia — Grade 34
Breast Edema — Grade 110
Breast Edema — Grade 20
Breast Edema — Grade 31
Breast Pain — Grade 128
Breast Pain — Grade 21
Breast Pain — Grade 30
Arm Lymphadema — Grade 11
Arm Lymphadema — Grade 20
Arm Lymphadema — Grade 31
SecondaryPatient Self-assessment of the Cosmetic Results
Time frame:
5 years
Reported as:
Count of participants · Participants
Patient Self-assessment of the Cosmetic Results
ParticipantsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Excellent/Good251
Fair56
Poor7
SecondarySurvival
Time frame:
5 years
Reported as:
Number · percentage of Patients
Survival
percentage of PatientsAccelerated Intensity Modulated Radiation Therapy (AIMRT)
Survival94.6

Adverse events

Collected over 5 Years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Accelerated Intensity Modulated Radiation Therapy (AIMRT)17/314 (5.4%)0/314 (0%)96/314 (30.6%)
Most frequent other events
Showing 10 of 82
Most frequent other events
EventAccelerated Intensity Modulated Radiation Therapy (AIMRT)
FatigueGeneral disorders46/314
Hot flashesEndocrine disorders42/314
ARTHRITISMusculoskeletal and connective tissue disorders4/314
PericarditisCardiac disorders2/314
HypertensionCardiac disorders1/314
Hemolitic autoimmune anemiaBlood and lymphatic system disorders1/314
DepressionNervous system disorders1/314
PAIN lower extremitiesNervous system disorders1/314
Hair lossSkin and subcutaneous tissue disorders1/314
Bone PainMusculoskeletal and connective tissue disorders1/314

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Accelerated Intensity Modulated Radiation Therapy (AIMRT)
<=18 years0
Between 18 and 65 years188
>=65 years126
Sex: Female, Male
Sex: Female, Male(Participants)Accelerated Intensity Modulated Radiation Therapy (AIMRT)
Female314
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Accelerated Intensity Modulated Radiation Therapy (AIMRT)
White220
Black60
Asian22
Hispanic12
Region of Enrollment
Region of Enrollment(Participants)Accelerated Intensity Modulated Radiation Therapy (AIMRT)
United States314
08

Study locations

1 site
  • NYU Langone Medical Center
    New York, New York 10003, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02606708
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Feb 20, 2005
Primary completion
Jun 2, 2016
Completion
Jun 2, 2017
Results posted
Aug 14, 2020
Last update
Aug 14, 2020

Study contacts

Carmen Perez, MD
principal investigator · NYU Langone Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion